Beurs gesloten -
NSE India S.E.
13:43:49 03-05-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
537
INR
|
-3,12%
|
|
-1,29%
|
+62,59%
|
Fiscaal tijdperk: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
37.259
|
27.735
|
19.933
|
27.214
|
34.473
|
19.908
|
Bedrijfswaarde
1 |
37.238
|
29.335
|
23.410
|
34.445
|
41.053
|
27.699
|
K/w-verhouding
|
35,6
x
|
24,7
x
|
12,8
x
|
18,4
x
|
54,7
x
|
-61,3
x
|
Dividendrendement
|
0,15%
|
0,29%
|
0,45%
|
0,33%
|
0,28%
|
-
|
Marktkapitalisatie/omzet
|
4,72
x
|
3,78
x
|
2,19
x
|
3,02
x
|
3,01
x
|
1,89
x
|
Bedrijfswaarde/omzet
|
4,72
x
|
4
x
|
2,58
x
|
3,82
x
|
3,58
x
|
2,63
x
|
Bedrijfswaarde/EBITDA
|
24,7
x
|
19
x
|
10,9
x
|
20,2
x
|
20,7
x
|
32
x
|
Bedrijfswaarde/FCF
|
-38,1
x
|
-13,1
x
|
-10,5
x
|
-8,55
x
|
-17,5
x
|
-25,1
x
|
FCF Yield
|
-2,63%
|
-7,62%
|
-9,56%
|
-11,7%
|
-5,72%
|
-3,98%
|
Price to Book
|
3,49
x
|
2,32
x
|
1,5
x
|
1,84
x
|
1,89
x
|
1,12
x
|
Aantal aandelen (in duizenden)
|
80.127
|
81.527
|
81.527
|
81.527
|
86.802
|
86.802
|
Referentieprijs
2 |
465,0
|
340,2
|
244,5
|
333,8
|
397,2
|
229,4
|
Datum van publicatie
|
28/08/18
|
29/08/19
|
15/08/20
|
4/09/21
|
5/09/22
|
5/09/23
|
Fiscaal tijdperk: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
7.894
|
7.337
|
9.082
|
9.016
|
11.469
|
10.517
|
EBITDA
1 |
1.509
|
1.545
|
2.144
|
1.709
|
1.981
|
865,4
|
Bedrijfsresultaat (EBIT)
1 |
1.148
|
1.141
|
1.723
|
1.188
|
1.204
|
-54
|
Operationele Marge
|
14,54%
|
15,55%
|
18,97%
|
13,17%
|
10,5%
|
-0,51%
|
Resultaat voor belastingen (EBT)
1 |
1.368
|
1.357
|
1.881
|
1.951
|
1.023
|
-382,8
|
Nettowinst (verlies)
1 |
1.052
|
1.123
|
1.562
|
1.478
|
606,6
|
-324,8
|
Nettomarge
|
13,33%
|
15,3%
|
17,19%
|
16,39%
|
5,29%
|
-3,09%
|
WPA
2 |
13,07
|
13,77
|
19,15
|
18,13
|
7,260
|
-3,741
|
Free Cash Flow
1 |
-978,2
|
-2.234
|
-2.238
|
-4.028
|
-2.348
|
-1.104
|
FCF-marge
|
-12,39%
|
-30,46%
|
-24,64%
|
-44,67%
|
-20,47%
|
-10,5%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
2 |
0,7000
|
1,000
|
1,100
|
1,100
|
1,100
|
-
|
Datum van publicatie
|
28/08/18
|
29/08/19
|
15/08/20
|
4/09/21
|
5/09/22
|
5/09/23
|
Fiscaal tijdperk: März |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Omzet
1 |
1.912
|
2.080
|
2.374
|
2.953
|
2.723
|
3.406
|
2.612
|
2.629
|
2.625
|
EBITDA
1 |
209,7
|
262,5
|
318,8
|
531,6
|
450,9
|
737,3
|
205,7
|
122
|
312,9
|
Bedrijfsresultaat (EBIT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operationele Marge
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Resultaat voor belastingen (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettowinst (verlies)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettomarge
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
WPA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
13/02/21
|
31/05/21
|
14/08/21
|
29/10/21
|
8/02/22
|
23/05/22
|
11/08/22
|
11/11/22
|
14/02/23
|
Fiscaal tijdperk: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
1.599
|
3.477
|
7.231
|
6.579
|
7.791
|
Nettokaspositie
1 |
21,2
|
-
|
-
|
-
|
-
|
-
|
Hefboom (schuld/ebitda)
|
-
|
1,035
x
|
1,622
x
|
4,23
x
|
3,322
x
|
9,002
x
|
Free Cash Flow
1 |
-978
|
-2.234
|
-2.238
|
-4.028
|
-2.348
|
-1.104
|
ROE (netto-inkomsten/eigen vermogen)
|
9,97%
|
9,65%
|
12,3%
|
10,5%
|
3,7%
|
-1,72%
|
ROA (netto-inkomsten/totale activa)
|
4,78%
|
4,59%
|
5,99%
|
3,21%
|
2,73%
|
-0,12%
|
Totale activa
1 |
22.039
|
24.478
|
26.072
|
46.059
|
22.200
|
278.051
|
Nettoactief per aandeel
2 |
133,0
|
147,0
|
163,0
|
181,0
|
210,0
|
205,0
|
Cashflow per aandeel
2 |
9,030
|
4,200
|
5,440
|
15,10
|
3,900
|
2,460
|
Capex
1 |
1.380
|
3.000
|
3.493
|
3.542
|
3.318
|
2.725
|
Capex/omzet
|
17,48%
|
40,89%
|
38,46%
|
39,29%
|
28,93%
|
25,91%
|
Datum van publicatie
|
28/08/18
|
29/08/19
|
15/08/20
|
4/09/21
|
5/09/22
|
5/09/23
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| +26,08% | 662 mld. | | +21,85% | 546 mld. | | -4,77% | 359 mld. | | +16,97% | 323 mld. | | +5,69% | 290 mld. | | +13,68% | 234 mld. | | +3,65% | 198 mld. | | -11,12% | 194 mld. | | -3,40% | 157 mld. |
Farmaceutische producten - Andere
|